The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Managing Waldenström’s in 2024: optimizing the BTKi backbone & moving towards fixed-duration therapy
Christian Buske, MD, University Hospital Ulm, Ulm, Germany, comments on the current management of Waldenström’s macroglobulinemia (WM), highlighting that a tendency towards chemotherapy-free approaches is being observed. Prof. Bruske emphasizes the need to optimize the BTK inhibitor (BTKi) backbone of treatment regimens and hopefully move towards fixed-duration therapy for patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think what we have seen and I just mentioned our own clinical study, which we are presenting here at ASH, is there’s a clear tendency towards chemotherapy-free approaches. And I think covalent BTK inhibitors, ibrutinib or second-generation zanubrutinib, they are the backbone of treatment and we try as done by our own trial to optimize this let’s say BTKi backbone, in our case by adding rituximab and bortezomib, but there are also other presentations here at ASH for instance using pirtobrutinib a non-covalent BTK inhibitor to combine it for instance with venetoclax to also try to limit the duration of treatment, which in the case of Waldenström at the moment still is non-fixed duration treatment with ibrutinib or zanubrutinib...
I think what we have seen and I just mentioned our own clinical study, which we are presenting here at ASH, is there’s a clear tendency towards chemotherapy-free approaches. And I think covalent BTK inhibitors, ibrutinib or second-generation zanubrutinib, they are the backbone of treatment and we try as done by our own trial to optimize this let’s say BTKi backbone, in our case by adding rituximab and bortezomib, but there are also other presentations here at ASH for instance using pirtobrutinib a non-covalent BTK inhibitor to combine it for instance with venetoclax to also try to limit the duration of treatment, which in the case of Waldenström at the moment still is non-fixed duration treatment with ibrutinib or zanubrutinib. So clearly the trend goes towards chemotherapy-free treatment and I think in the future we will try to establish regimens which allow us to give chemotherapy-free approaches as a fixed-duration treatment for one or two years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Roche/Genentech: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; BeiGene: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead Sciences: Consultancy, Honoraria, Speakers Bureau; Celltrion: Consultancy, Honoraria, Research Funding, Speakers Bureau; MorphoSys: Consultancy, Honoraria, Speakers Bureau; Regeneron: Consultancy, Honoraria, Speakers Bureau; Sobi: Consultancy, Honoraria, Speakers Bureau; Lilly: Consultancy, Honoraria, Speakers Bureau; MSD: Research Funding; Amgen: Research Funding.
